Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney ...

A dose of an experimental drug reduced the levels of a fatal type of cholesterol for up to a year despite previous knowledge that it's untreatable. NBC News reported that pharmaceutical company Eli ...

Eli Lilly focuses on genetic medicine, developing treatments for diabetes, heart disease, deafness, Parkinson's, and Alzheimer's. Expanding in India.

Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

Even statins don’t work on risk factor called lipoprotein (a) that quickly clings to arteries and narrows them ...

On Sunday, researchers announced that an experimental drug from Eli Lilly, lepodisiran, reduced levels of Lp (a) by a ...

Patients at risk for heart disease experienced significant reductions in apolipoprotein B and LDL cholesterol levels on ...

Eli Lilly rolled out positive Phase 2 results for lepodisiran, a therapy targeting lipoprotein(a)—that genetic party crasher ...

“Nearly a quarter of the world’s population has elevated levels of Lp (a), putting them at a significantly higher risk of cardiovascular events such as heart attacks and strokes,” said Steven Nissen, ...

Eli Lilly (NYSE: LLY) is advancing its ambitions in cardiometabolic medicine with new mid-stage data showing that solbinsiran ...

Inherited or genetic heart disorders, mostly known as Hypertrophic cardiomyopathy (HCM) in medical term, is a condition affecting the left ventricle, the main p ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.